Intrinsic Therapeutics completed a US $52MM Series Growth equity financing. Proceeds will support U.S. commercialization of the Barricaid® anular closure device, which is used after discectomy to treat herniated discs. In all, the company has raised ~$219MM in over 10 rounds of funding to date.
The company received FDA Premarket Approval for Barricaid in 1Q19.
Questa Capital led this funding round, with participation from existing investors New Enterprise Associates, Greenspring Associates, Quadrille and Delos Capital.
Intrinsic Therapeutics completed a US $52MM Series Growth equity financing. Proceeds will support U.S. commercialization of the Barricaid® anular closure device, which is used after discectomy to treat herniated discs. In all, the company has raised ~$219MM in over 10 rounds of funding to date.
The company received FDA Premarket Approval for...
Intrinsic Therapeutics completed a US $52MM Series Growth equity financing. Proceeds will support U.S. commercialization of the Barricaid® anular closure device, which is used after discectomy to treat herniated discs. In all, the company has raised ~$219MM in over 10 rounds of funding to date.
The company received FDA Premarket Approval for Barricaid in 1Q19.
Questa Capital led this funding round, with participation from existing investors New Enterprise Associates, Greenspring Associates, Quadrille and Delos Capital.
Copy to clipboard 
